Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: A systematic review

British Journal of Cancer

Volumn 96, Issue 2, 2007, Pages 226-230

  Bryant, J ^a   Picot, J ^a   Baxter, L ^a   Levitt, G ^b   Sullivan, I ^b   Clegg, A ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Anthracyclines; Cardioprotection; Children; Systematic review

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DOXORUBICIN; RAZOXANE; TROPONIN T; UBIDECARENONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG EFFICACY; DRUG INFUSION; ECHOCARDIOGRAPHY; ECONOMIC EVALUATION; HEALTH CARE COST; HEART DISEASE; HEART FUNCTION; HEART PERFORMANCE; HEART PROTECTION; HUMAN; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SIDE EFFECT; STANDARD; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TROPONIN T BLOOD LEVEL;

ANTHRACYCLINES; CARDIOTONIC AGENTS; CHILD; HUMANS; STATE MEDICINE;

EID: 33846530536     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603562     Document Type: Review

References (18)

1. Batist G, Ramakriskan G, Sekhar Rao C, Chandrasekharan A, Gutheil J, Guthrie T (2001) Reduced cardiotoxicity and preserved antitumour efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomised multicentre trial of metastatic breast cancer. JClin Oncol 19: 1444-1454
2. Bonadonna G, Monfardini S (1969) Cardiac toxicity of daunorubicin. Lancet 1: 837
3. Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A (In Press) Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess
4. Bu'Lock FA, Mott MG, Oakhill A, Martin RP (1996) Early identification of anthracycline cardiomyopathy: Possibilities and implications. ArchDisChildhood 75: 416-422
5. CRD (2001) Undertaking Systematic Reviews of Research on Effectiveness. 4. York, Centre for Reviews and Dissemination
6. Curry H, Parkes S, Powell J, Mann J (2006) Caring for survivors of childhood cancers: the size of the problem. Eur J Cancer 42: 501-508
7. Hellmann K (1996) Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care. Supportive Care in Cancer 4: 305-307
8. Hewitt M, Weiner SL, Simone JV (2003) Childhood Cancer Survivorship: Improving care and Quality of Life. Washington, DC: National Academies Press
9. Iarussi D, Auricchio U, Agretto A, Murano A, Giuliano M, Casale F, Indolfi P, Lacono A (1994) Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 15: S207-S212
10. Levitt GA, Dorup I, Sorensen K, Sullivan I (2004) Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol 124: 463-468
11. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball DV, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. JClin Oncol 20: 1677-1682
12. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351: 145-153
13. Lipshultz SE, Sallan SE, Giantris AL, Lipsitz SR, Dalton V, Colan SD (1998) 48 h continuous doxorubicin infusion is not cardioprotective in children assessed 18 months later: the DFCI 91001 ALL protocol. Proc Am Soc Clin Oncol 17: 528a
14. Myers C (1998) The role of iron in doxorubicin-induced cardiomyopathy. Semi Oncol 25: 10-14
15. National Institute for Health and Clinical Excellence (2005) Improving Outcomes with Children and Young People with Cancer - Manual Update. 1 - 198. London: National Institute for Health and Clinical Excellence
16. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID (2003) Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 97: 1991-1998
17. Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G (1993) Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer 72: 3120-3130
18. van Dalen EC, Caron HN, Dickinson HO, Kremer LCM (2005) Cardioprotective interventions for cancer patients receiving anthracyclines [Issue 1, Cochrane review]. In: Cochrane Database of Systematic Reviews 2005 Issue. Chichester, UK: John Wiley & Sons, Ltd